Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical Limited announced promising phase III results for their drug Culmerciclib, showing effectiveness in treating advanced breast cancer when paired with Fulvestrant. This innovative treatment significantly reduced disease progression or death in patients, and is expected to be the first of the Group’s drugs approved for breast cancer treatment. Further details of their study will be unveiled at the 2024 CSCO Annual Meeting.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
